Chiasma Inc

Chiasma — Merger or Acquisition (May 2021)

36 slides from Chiasma's merger presentation, May 5, 2021

  1. Slide 1: Filed by Amryt Pharma plc under Rule 425

    Filed by Amryt Pharma plcThis communication is filed pursuant to Rule 425 under the United States Securities Act of 1933Subject Company: Chiasma, Inc.(Commission File No. 000-37500)Date: May 5, 2021 The following is a presentation made to investors and analysts by Amryt Pharma on May 5, 2021:

  2. Slide 2: Amryt Pharma Acquisition of Chiasma Inc May 2021

    Amryt pharma acquisition of chiasma inc May 2021

  3. Slide 3: Disclaimer

    DisclaimeR 2 This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. By receiving this presentation and/or attending the meeting where

  4. Slide 4: Forward-looking statements

    This press release may contain forward-looking statements containing the words “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project” and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this

  5. Slide 5: Additional Information

    ADDITIONAL INFORMATION No Offer or SolicitationThis communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdictio

  6. Slide 6: Amryt Acquisition of Chiasma - Transaction Benefits

    Amryt acquisition of chiasma - Transaction BENEFITS Strengthens Amryt’s global leadership in developing and commercializing transformative therapies for rare & orphan diseasesCombined business will have three approved commercial products lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalep

  7. Slide 7: Transaction Benefits contd.

    Transaction BENEFITS contd. 6 a global leader in rare & orphan diseases Lead pipeline candidate Oleogel-S10*(Filsuvez®) under regulatory review in US and EU Acquisition leverages Amryt’s proven commercial execution ability expertise, global infrastructure and integration capabilities to accelerate M

  8. Slide 8: Combined Commercial Products

    Combined Commercial Products 2 marketed products with multiple lifecycle extension opportunities 1 marketed product in first full year of launch 3 marketed products with strong IP protection Infrastructure Global medical + commercial US medical + commercial Enhanced US plus global medical + commerci

  9. Slide 9: Amryt Corporate Overview

    AMRYT CORPORATE OVERVIEW 8 GLOBAL, COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO ACQUIRING, DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR RARE DISEASES EBITDA positive and growing commercial business with two commercial products (metreleptin and lomitapide) and a significant developm

  10. Slide 10: Consistent Performance and Growth

    CONSISTENT PERFORMANCE AND GROWTH 9 * Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2019. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out-

  11. Slide 11: Metreleptin - Lipodystrophy Market Overview

    Metreleptin - LIPODYSTROPHY Market Overview The global market LD market is estimated at $530 million with US estimated at ~$280 million Fatty liver Insatiable appetite Chronic fatigue Diabetes Pancreatitis Organ damage Reduced life expectancy Lipodystrophy is a chronic condition associated with low

  12. Slide 12: Lomitapide - HoFH Market Overview

    LOMITAPIDE - HoFH Market Overview Lomitapide is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal treatments for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia (“HoFH”) in the US, Canada, Columbia, Argentina and Japan (under the trade n

  13. Slide 13: Oleogel-S10: Potential first in market therapy for epidermolysis bullosa

    Oleogel-s10: Potential first in market therapy for epidermolysis bullosa Regulatory submissions filed with FDA and EMA. If approved, US launch anticipated Q4 2021 EU anticipated Q2 2022 Received Fast Track DesignationGranted Rare Pediatric Disease Designation by FDA The global market is estimated to

  14. Slide 14: Growing Commercial Portfolio & Enhanced Combined Development Pipeline

    GROWING COMMERCIAL PORTFOLIO & ENHANCED COMBINED Development Pipeline 13 EARLY AND LATE-STAGE PIPELINE WITH MULTIPLE VALUE INFECTION POINTS Definitions: Dystrophic EB (“DEB”); Junctional EB (‘‘JEB’’); Recessive Dystrophic EB (‘‘RDEB’’) * Upcoming clinical milestones are subject to the impact of COVI

  15. Slide 15: Global Infrastructure

    GLOBAL INFRASTRUCTURE INFRASTRUCTURE IN PLACE TO DRIVE GLOBAL GROWTH 7 Current markets Pending markets Out-licensed BA Pharma Trading Ltd 14

  16. Slide 16: Chiasma Overview

    CHIASMA Overview 15 MYCAPSSA® was approved by FDA in June 2020 and launched in September 2020 as the first and only oral (SSA) for patients with acromegaly Significant market potential for MYCAPSSA® in NET Patent protection for MYCAPSSA® in the US and EU to 2029 with method of use coverage in US to

  17. Slide 17: MYCAPSSA - Acromegaly US Market Overview

    MycapSsa® - Acromegaly - US Market Overview 16 Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments Injections Present Significant Challenges to Patients** The global market for SSAs in the treatment of acromegaly is estimated at ~$800 million with US estima

  18. Slide 18: Strategic Intent: make MYCAPSSA the new standard of care

    STRATEGIC Intent: to make MYCAPSSA® the NEW pharmacological standard of care Patients2 Over 185M Lives Covered3 Compelling Value for Payers Positive Patient Feedback Oral Option addresses unmet needSSAs already reimbursed and in payers’ budgetsMYCAPSSA® pricing designed to facilitate broad access Pa

  19. Slide 19: Global SSA Sales expected to be ~$3.8B by 2028

    Global SSA Sales expected to be ~$3.8B by 2028 18 $2.3B $2.8B $2.6B $3.8B $0.8B $1.9B $0.1B $1.1B $2.4B $0.3B Financial reports & filings, Novartis & Ipsen, 2016–2019Future projected growth at 3.5% to 202855% of global sales in US market (Novartis Annual Report for sales in 2019) Other

  20. Slide 20: Neuroendocrine Tumor (NET) - Market Overview

    Neuroendocrine Tumor (NET) - Market Overview 19 Octreotide LAR and lanreotide depot injections are broadly used as first-line pharmacological treatments Potential addressable patient population on SSAs estimated at ~24,000 in the US2 NET Symptoms Include: GI Tract Malignancies Diarrhea & Constipatio

  21. Slide 21: TPE - Validated delivery technology platform

    TPE - Validated delivery technology platform 20 Capsules with TPE technology have an enteric coating to protect against degradation in the stomach. Once in the small intestine, the capsule is designed to dissolve and release the TPE formulation. TPE technology induces the reversible expansion of tig

  22. Slide 22: Chiasma - Rationale for the combination

    CHIASMA – Rationale for the combination 21 The combination with AMRYT is expected to: Capitalize on Amryt’s financial strength to expand the potential benefits of MYCAPSSA® in NET and other new development opportunities with our TPE technology platform Provide a faster path to profitability and grea

  23. Slide 23: Combination delivers long term value to patients and shareholders

    COMBINATION DELIVERS LONG TERM VALUE TO PATIENTS AND SHAREHOLDERS Leading global commercial-stage orphan disease company with three growing marketed products in large attractive markets with active development / life cycle opportunities to expand to new indications 22 Combination represents a compel

  24. Slide 24: Questions & Answers

    Answers Questions & 23

  25. Slide 25: Q1 2021 Financial Results and Outlook

    Q1 2021 FINANCIAL RESULTS AND CORPORATE UPDATE May 5, 2021

  26. Slide 26: Disclaimer

    DisclaimeR 25 This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. By receiving this presentation and/or attending the meeting where

  27. Slide 27: Forward-looking statements

    FORWARD-LOOKING STATEMENTS 26 This press release may contain forward-looking statements containing the words “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project” and similar expressions (or their negative) identify certain of these forward-looking statements. The forwa

  28. Slide 28: Additional Information

    ADDITIONAL INFORMATION No Offer or SolicitationThis communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdictio

  29. Slide 29: Q1 highlights

    Q1 highlights Continued positive momentum and growth in our commercial businessDelivered double digit organic revenue growthRaising our revenue guidance for FY 2021Reimbursement approval for metreleptin in England, Wales and FrancePositive feedback from the FDA on the path forward for metreleptin in

  30. Slide 30: Consistent Performance and Growth

    CONSISTENT PERFORMANCE AND GROWTH 29 * Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2019. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out

  31. Slide 31: Metreleptin - balanced growth across all regions

    METRELEPTIN - balanced growth across all regions 30 Global metreleptin growth of 25% in 2020 OVER 2019, delivering revenues of $107M* Average Quarterly Growth 6.6% * Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Am

  32. Slide 32: Lomitapide - growth being driven by EMEA performance

    lomitapide - growth being driven by emea performance 31 Global lomitapide growth of 10% in 2020 OVER 2019, delivering revenues of $75M* * Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on

  33. Slide 33: Oleogel-S10 Potential first in market therapy for epidermolysis bullosa

    Oleogel-s10 32 Potential first in market therapy for epidermolysis bullosa Completed the rolling submission of an NDA to the FDA NDA submission includes a request for Priority Review Oleogel-S10 has been granted Orphan, Fast Track and Pediatric Rare Disease designation by the FDA European Medicines

  34. Slide 34: IFRS and Non-GAAP Adjusted Results - Q1 2021 EBITDA

    Ifrs and non-gaap adjusted RESULTS – q1 2021 Ebitda 33 US$M Q1 2021(unaudited) Q1 2021 Non-cash Items1 Q1 2021 Non-GAAP Adjusted Revenue 48.4 - 48.4 Cost of sales (23.5) 11.7 (11.8) Gross profit 24.9 11.7 36.7 R&D expenses (8.9) - (8.9) SG&A expenses (18.2) 0.3 (17.9) Share based compensation expens

  35. Slide 35: Amryt post Chiasma acquisition

    Amryt post chiasma acquisition* Building a global leader in rare diseases Financial flexibility to execute on growth plans 34 Global commercial infrastructure and experienced team in place to drive product launches and growth Revenue generating commercial portfolio with three approved commercial pro

  36. Slide 36: Questions & Answers

    Answers Questions & Important Additional Information and Where to Find It In connection with the proposed acquisition, Amryt intends to file a registration statement on Form F-4 with the SEC, which will include a document that serves as a prospectus of Amryt and a proxy statement of Chiasma (the “pr

Chiasma — Merger or Acquisition (May 2021) on 6ix